AMAXPAR:ALAMA +8.46%28 EPS without NRI is €-0.15 as of Dec. 2025. GuruFocus rates XPAR:ALAMA with a GF Score™ of 28/100 and a GF Value™ of €0.16 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 513 Healthcare Providers & Services companies, AMA ranks better than 86.74% on this metric.
AMA's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was €-0.10.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.15.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 48.20% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 21.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for AMA's EPS without NRI or its related term are showing as below:
XPAR:ALAMA'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -46.3 Med: 19.95 Max: 48.2
Current: 48.2
During the past 8 years, AMA's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 48.20% per year. The lowest was -46.30% per year. And the median was 19.95% per year.
XPAR:ALAMA's 3-Year EPS without NRI Growth Rate is ranked better than 86.74% of 513
companies
in the Healthcare Providers & Services industry
Industry Median: 11.6
vs XPAR:ALAMA: 48.20
AMA's EPS (Diluted) for the
six
months ended in Dec. 2025 was €-0.10.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.15.
AMA's EPS (Basic) for the
six
months ended in Dec. 2025 was €-0.10.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.15.
AMA (XPAR:ALAMA) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
AMA EPS without NRI Related Terms
AMA EPS without NRI Historical Data
* Premium members only.
The historical data trend for AMA's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALAMA vs VEEV, BTSG, TEM: EPS without NRI Comparison
For the Health Information Services subindustry, AMA's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AMA PE Ratio without NRI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, AMA's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where AMA's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.15
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMA (XPAR:ALAMA) has a EPS without NRI of €-0.15 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on AMA and its competitors. According to the industry distribution chart, AMA ranks #68 out of 513 companies in the Healthcare Providers & Services industry, placing it in the top 13.3%.
Is AMA's EPS without NRI too high?
AMA's current EPS without NRI is €-0.15. Based on the distribution chart, AMA ranks #68 out of 513 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, AMA has a GF Score™ of 28/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AMA's EPS without NRI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, AMA ranks #68 out of 513 companies for EPS without NRI. This places AMA in the top 13% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 11.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.60, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on AMA and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AMA's current EPS without NRI is €-0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AMA stock overvalued right now?
Based on GuruFocus' analysis, AMA (XPAR:ALAMA) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.16, compared to a current price of €0.14 — trading 11.9% below its estimated fair value. The current EPS without NRI is €-0.15. AMA's overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For AMA (XPAR:ALAMA), the current EPS without NRI is €-0.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AMA (XPAR:ALAMA) Overvalued in 2026?
Based on GuruFocus' analysis, AMA stock appears to be undervalued.
The current stock price of €0.14 is trading 11.9% below its estimated GF Value™ of €0.16.
GuruFocus considers AMA to be Modestly Undervalued.
Key valuation signals for XPAR:ALAMA:
EPS without NRI: €-0.15
GF Value™: €0.16 vs. price of €0.14 (11.9% below fair value)
No single metric tells the full story. See the XPAR:ALAMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AMA Corp PLC specializes in the development of remote assistance, inspection, and training solutions involving connected glasses, a dedicated smartphone, and external video sources such as webcams, thermographic cameras, endoscopes, microscopes, and others. Geographically the company operates in European segment, which includes subsidiaries in France, Germany, the UK, Romania, Italy and Spain and which invoice customers in Europe; North American segment, which includes subsidiaries in the United States and Canada and which invoice customers in the North American area; and lastly Asian segment, which includes subsidiaries in Hong Kong, Shanghai and Japan and which invoice customers in the Asia area.
28GF Score
Get the complete analysis for XPAR:ALAMA
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALAMA has been successfully added to your 
